Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial

BMC Pulmonary Medicine

Research Article

Frances Mair¹  Charles McSharry²  Iona Donnelly²  Lisa Jolly²  Christopher J Weir³  Jane Lafferty⁴  Georgina Braganza⁴  Rekha Chaudhuri⁴  Neil C Thomson⁴  Mark Spears⁴  Suzanne M Lloyd⁵ 

[1] General Practice, University of Glasgow, Glasgow, UK;Immunology, Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK;MRC Hub for Trials Methodology Research, University of Edinburgh, UK;Respiratory Medicine, Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK;Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK;

关键词: Asthma;    Atorvastatin;    Asthma Control;    Peak Expiratory Flow;    Human Airway Smooth Muscle Cell;   

DOI  :  10.1186/1471-2466-11-16

 received in 2010-11-24, accepted in 2011-04-07,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundThe immune modulating properties of statins may benefit smokers with asthma. We tested the hypothesis that short-term treatment with atorvastatin improves lung function or indices of asthma control in smokers with asthma.MethodsSeventy one smokers with mild to moderate asthma were recruited to a randomized double-blind parallel group trial comparing treatment with atorvastatin (40 mg per day) versus placebo for 4 weeks. After 4 weeks treatment inhaled beclometasone (400 μg per day) was added to both treatment arms for a further 4 weeks. The primary outcome was morning peak expiratory flow after 4 weeks treatment. Secondary outcome measures included indices of asthma control and airway inflammation.ResultsAt 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p = 0.449], but there was an improvement with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p = 0.005]. There was no significant improvement with atorvastatin and inhaled beclometasone compared to inhaled beclometasone alone in outcome measures at 8 weeks.ConclusionsShort-term treatment with atorvastatin does not alter lung function but may improve asthma quality of life in smokers with mild to moderate asthma.Trial RegistrationClinicaltrials.gov identifier:NCT00463827

【 授权许可】

Unknown   
© Braganza et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.